Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity; [Сравнительная Характеристика Кардиопротекторных Эффектов Дапаглифлозина И Триметазидина На Модели Доксорубицин-Циклофосфамидной Кардиотоксичности] Publisher



Avagimyan AA1, 11 ; Trofimenko AI2 ; Sheibani M3 ; Kakturskiy LV4 ; Urazova OI5 ; Navasardyan GA1 ; Jndoyan ZT1 ; Sulashvili NV6 ; Gabunia LI6 ; Gorgaslidze NS6 ; Khamidova FM7 ; Martemyanova LA8 ; Pogosova NV9 ; Sarrafzadegan N10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  2. 2. Kuban State Medical University, Krasnodar, Russian Federation
  3. 3. Iran University of Medical Sciences, Tehran, Iran
  4. 4. Russian Scientific Center of Surgery named after Academician B.V. Petrovsky, Moscow, Russian Federation
  5. 5. Siberian State Medical University, Tomsk, Russian Federation
  6. 6. Tbilisi State Medical University, Tbilisi, Georgia
  7. 7. Samarkand State Medical University, Samarkand, Uzbekistan
  8. 8. Gomel State Medical University, Gomel, Belarus
  9. 9. National Medical Research Centre of Cardiology named after Academician E.I. Chazov, Moscow, Russian Federation
  10. 10. Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  11. 11. Yerevan State Medical University after M. Heratsi, 2a Koryun St, Yerevan, 0025, Armenia

Source: Innovative Medicine of Kuban Published:2023


Abstract

Background: Data published by task groups of the Ministry of Health of the Russian Federation, the European Society of Cardiol¬ogy, and other medical associations and institutions show that chemotherapy-induced cardiomyopathy is still a challenging issue that requires further research. Objective: To compare the cardioprotective potential of trimetazidine and dapagliflozin in a rat model of doxorubicin-cyclophospha¬mide cardiomyopathy. Materials and methods: Our randomized in vivo experimental study included 80 Wistar female rats. Doxorubicin and cyclophospha¬mide were administered at a dose of 15 mg/kg and 150 mg/kg, respectively. Trimetazidine (42 mg/kg) and dapagliflozin (14 mg/kg) were additionally administered to groups 3 and 4, respectively. The total duration of the experiment was 14 days. Results: Doxorubicin+cyclophosphamide mode of chemotherapy induces the development of toxic-ischemic cardiomyopathy. The trimetazidine and dapagliflozin administration was accompanied by stabilization of cardiovascular parameters. Comparison of both drugs' cardioprotective properties revealed a clear advantage of dapagliflozin over trimetazidine, especially in terms of such an important indicator as N-terminal pro-B-type natriuretic peptide. Conclusions: Further research aimed at exploring the cardioprotective potential of dapagliflozin against cardiovascular complications of chemotherapy is justified from a pathogenetic point of view. © 2023 Chinese Journal of Experimental Traditional Medical Formulae. All rights reserved.
Related Docs
View other Related Docs
1. Possibilities of Dapagliflozin-Induced Cardioprotection on Doxorubicin + Cyclophosphamide Mode of Chemotherapy-Induced Cardiomyopathy, International Journal of Cardiology (2023)
2. Trimetazidine As a Modifier of Chemotherapy-Induced Cardiovascular Redox-Homeostasis Disturbances, Kardiologija v Belarusi (2022)
3. Cardioprotective Potential of Protocatechuic Acid Against Doxorubicin-Induced Cardiotoxicity in Rats, Research in Pharmaceutical Sciences (2025)
4. Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model, Current problems in cardiology (2025)
5. Doxorubicin-Related Cardiotoxicity: Review of Fundamental Pathways of Cardiovascular System Injury, Cardiovascular Pathology (2024)
6. Genetically Engineered Mouse Embryonic Stem Cell-Derived Cardiomyocytes As a Suitable Model on Drugs Toxicity Assessment in Vitro, Journal of Isfahan Medical School (2014)
7. Pharmacological Interventions for Preventing Anthracycline-Induced Clinical and Subclinical Cardiotoxicity: A Network Meta-Analysis of Metastatic Breast Cancer, Journal of Oncology Pharmacy Practice (2021)
8. Cardioprotective Effect of Vanillic Acid Against Doxorubicin-Induced Cardiotoxicity in Rat, Research in Pharmaceutical Sciences (2020)
Experts (# of related papers)
View all Related Experts
Nizal Sarrafzadegan (7)
Davood Shafie (3)
Other Related Docs
9. Cardiac Sarcoidosis: A Contemporary Concept of Forgotten Granulomatosis, ARYA Atherosclerosis (2023)
10. Daunomycin-Related Cardiomyopathy in Children and Adolescents With Improved Acute Lymphoblastic Leukemia and Its Relationship With Cardiac Troponin-T Levels, Journal of Isfahan Medical School (2011)
11. Cytotoxic Effect of Pluronic F127-Poly (Methyl Vinyl Ether-Alt-Maleic Acid) Micelles Loaded With Doxorubicin on Mcf-7 Cells, Journal of Isfahan Medical School (2013)
12. Ac-Mode of Chemotherapy As a Trigger of Cardiac Syndrome X: A Case Study, Current Problems in Cardiology (2022)
13. Anthracycline Associated Disturbances of Cardiovascular Homeostasis, Current Problems in Cardiology (2022)
14. Antiapoptotic and Anti-Inflammatory Effects of Pparγ Agonist, Pioglitazone, Reversed Dox-Induced Cardiotoxicity Through Mediating of Mir-130A Downregulation in C57bl/6 Mice, Journal of Biochemical and Molecular Toxicology (2022)
15. Evaluation of the Central and Peripheral Effects of Doxepin on Carrageenan-Induced Inflammatory Paw Edema in Rat, Research in Pharmaceutical Sciences (2017)
16. Doxepin Prevents the Expression and Development of Paclitaxel-Induced Neuropathic Pain, Advanced Biomedical Research (2021)
17. Effects of Noradrenaline and Kcl on Peripheral Vessels in Doxorubicin Induced Model of Heart Failure, Pathophysiology (2002)
18. The Effect of Mebudipine on Cardiac Function and Activity of the Myocardial Nitric Oxide System in Ischaemia-Reperfusion Injury in Rats, Cardiovascular Journal of Africa (2011)
19. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 2)], Innovative Medicine of Kuban (2025)
20. Protective Effects of Protocatechuic Acid Against Doxorubicin- and Arsenic Trioxide-Induced Toxicity in Cardiomyocytes, Research in Pharmaceutical Sciences (2023)
21. Severe Mitral Regurgitation, an Unusual Manifestation of Chemotherapy-Induced Cardiotoxicity, Journal of Research in Medical Sciences (2017)